Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Assets (2016 - 2025)

Lineage Cell Therapeutics' Current Assets history spans 16 years, with the latest figure at $59.2 million for Q4 2025.

  • For Q4 2025, Current Assets rose 16.0% year-over-year to $59.2 million; the TTM value through Dec 2025 reached $59.2 million, up 16.0%, while the annual FY2025 figure was $59.2 million, 16.0% up from the prior year.
  • Current Assets reached $59.2 million in Q4 2025 per LCTX's latest filing, up from $42.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $111.5 million in Q4 2021 to a low of $34.4 million in Q3 2024.
  • Average Current Assets over 5 years is $57.4 million, with a median of $50.5 million recorded in 2024.
  • Peak YoY movement for Current Assets: surged 153.53% in 2021, then crashed 46.21% in 2022.
  • A 5-year view of Current Assets shows it stood at $111.5 million in 2021, then crashed by 46.21% to $60.0 million in 2022, then crashed by 35.93% to $38.4 million in 2023, then surged by 32.66% to $51.0 million in 2024, then grew by 16.0% to $59.2 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Current Assets are $59.2 million (Q4 2025), $42.3 million (Q3 2025), and $43.8 million (Q2 2025).